Satsuma Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder f…

Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Satsuma Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of STSA's Analysis
CIK: 1692830 CUSIP: 80405P107 ISIN: US80405P1075 LEI: - UEI: -
Secondary Listings
STSA has no secondary listings inside our databases.